Creso Pharma (CPH) has announced it will be changing its name to reflect its rebranding and growth strategies.
The medicinal cannabis company has proposed to change its name to Melodiol Global Health, a decision that stemmed from some recent acquisitions and is part of the company’s goal to expand across the US and other key markets.
Creso Pharma will need to secure shareholder approval for the name change, which it will seek at an upcoming general meeting. The company has also welcomed two new directors following the resignation of Non-Executive Director and Founder Adam Blumenthal.
Ben Quirin has joined the company as a Non-Executive Director. Mr. Quirin brings 20 years of global experience in the telecom, technology, and pharmaceutical sectors. He also brings valuable expertise in the cannabis sector after being the Managing Director of Canopy Growth which, based on market cap, was the world’s largest cannabis company in early 2019.
Creso will leverage his experience to drive product and brand growth in different markets, with a particular focus on the Asia-Pacific region. The company has also appointed Jodi Scott as Executive Director as part of the recent acquisition of Sierra Sage Herbs.
Read the entire article at The Market Herald